Two‐year crizotinib monotherapy induced durable complete response of pediatric ALK‐positive inflammatory myofibroblastic tumor

Pediatric Blood & CancerEarly View e30330 LETTER TO THE EDITOR Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor Akira Kaino, Akira Kaino orcid.org/0000-0001-6658-2988 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorHidetaka Niizuma, Corresponding Author Hidetaka Niizuma [email protected] orcid.org/0000-0002-3161-8968 Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan Correspondence Hidetaka Niizuma, Department of Pediatrics, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Email: [email protected]Search for more papers by this authorSaori Katayama, Saori Katayama orcid.org/0000-0001-8342-4578 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorMasahiro Irie, Masahiro Irie orcid.org/0000-0002-9446-6244 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorTomohiro Nakano, Tomohiro Nakano orcid.org/0000-0001-9534-5121 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorDaichi Sato, Daichi Sato Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorTsuyoshi Saito, Tsuyoshi Saito orcid.org/0000-0001-9690-8440 Department of Human Pathology, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorShunsuke Kato, Shunsuke Kato orcid.org/0000-0002-4860-1687 Department of Medical Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorYoshiyuki Suehara, Yoshiyuki Suehara orcid.org/0000-0001-8206-3037 Department of Medicine for Orthopaedics and Motor Organ, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorYoji Sasahara, Yoji Sasahara orcid.org/0000-0003-0030-1535 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorAtsuo Kikuchi, Atsuo Kikuchi orcid.org/0000-0003-1002-8739 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this author Akira Kaino, Akira Kaino orcid.org/0000-0001-6658-2988 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorHidetaka Niizuma, Corresponding Author Hidetaka Niizuma [email protected] orcid.org/0000-0002-3161-8968 Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan Correspondence Hidetaka Niizuma, Department of Pediatrics, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Email: [email protected]Search for more papers by this authorSaori Katayama, Saori Katayama orcid.org/0000-0001-8342-4578 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorMasahiro Irie, Masahiro Irie orcid.org/0000-0002-9446-6244 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorTomohiro Nakano, Tomohiro Nakano orcid.org/0000-0001-9534-5121 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorDaichi Sato, Daichi Sato Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorTsuyoshi Saito, Tsuyoshi Saito orcid.org/0000-0001-9690-8440 Department of Human Pathology, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorShunsuke Kato, Shunsuke Kato orcid.org/0000-0002-4860-1687 Department of Medical Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorYoshiyuki Suehara, Yoshiyuki Suehara orcid.org/0000-0001-8206-3037 Department of Medicine for Orthopaedics and Motor Organ, Juntendo University School of Medicine, Bunkyo, Tokyo, JapanSearch for more papers by this authorYoji Sasahara, Yoji Sasahara orcid.org/0000-0003-0030-1535 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this authorAtsuo Kikuchi, Atsuo Kikuchi orcid.org/0000-0003-1002-8739 Department of Pediatrics, Tohoku University School of Medicine, Sendai, JapanSearch for more papers by this author First published: 05 April 2023 https://doi.org/10.1002/pbc.30330 Akira Kaino and Hidetaka Niizuma contributed equally to this study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor. Am J Surg Pathol. 2007; 31: 509- 520. 2Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014; 4: 889- 895. 3Antonescu CR, Suurmeijer AJH, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015; 39: 957- 967. 4Suehara Y, Kohsaka S, Yamaguchi S, et al. Assessment of predictive biomarkers of the response to pazopanib based on an integrative analysis of high-grade soft-tissue sarcomas: analysis of a tumor sample from a responder and patients with other soft-tissue sarcomas. Clin Orthop Relat Res. 2020; 478: 2461- 2476. 5Casanova M, Brennan B, Alaggio R, et al. Inflammatory myofibroblastic tumor: the experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer. 2020; 127: 123- 129. 6Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group study. J Clin Oncol. 2017; 35: 3215- 3221. 7Trahair T, Gifford AJ, Fordham A, et al. Crizotinib and surgery for long-term disease control in children and adolescents with ALK-Positive inflammatory myofibroblastic tumors. JCO Precis Oncol. 2019; 3: 1- 11. PO.18.00297. 8Brivio E, Zwaan CM. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: efficacy and side effects. Pediatr Blood Cancer. 2019; 66:e27645. 9Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Prob Cancer. 2021; 45:100768. 10Mariño-Enríquez A, Wang W-L, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma. Am J Surg Pathol. 2011; 35: 135- 144. Early ViewOnline Version of Record before inclusion in an issuee30330 ReferencesRelatedInformation